

Women and Epilepsy

Sunila E. O'Connor, MD and Mary L. Zupanc, MD

Department of Neurology, Section of Child Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin

Women with epilepsy face additional challenges when compared to their peers. Hormonal influences may increase seizure activity, alter endocrine function, and affect fertility. In this population, antiepileptic drugs (AEDs) reduce the efficacy of contraception methods and increase the risk of fetal malformations. Other pertinent issues to women with epilepsy include breastfeeding as well as bone mineral health. This article summarizes our current, collective knowledge of these issues and makes specific recommendations with respect to management.

KEYWORDS antiepileptic drugs, breastfeeding, epilepsy, female, review, treatment

J Pediatr Pharmacol Ther 2009;14:212–220

INTRODUCTION

Epilepsy is a chronic neurological condition of unprovoked, recurrent seizures. The disorder affects approximately 1% of the population, including over one million women of childbearing age.¹ Women with epilepsy face additional challenges secondary to hormonal influences on seizure activity and endocrine function. In addition, antiepileptic drugs (AEDs) play a significant role regarding contraception, pregnancy/breastfeeding and bone health. The following discussion details potential complications and treatment dilemmas of women with epilepsy.

CATAMENIAL EPILEPSY

Catamenial epilepsy may be defined as a 2-fold increase in seizure occurrence during or just prior to menses.²⁻⁴ Depending on the method of data collection and definition used, the incidence of catamenial epilepsy ranges from 10%-78%.^{5,6} Herzog and colleagues described three patterns

of catamenial epilepsy—perimenstrual, periovulatory and luteal.^{7,8} They further reported seizure patterns of 184 females with refractory complex partial seizures as related to their ovulatory cycle.

ABBREVIATIONS AED, antiepileptic drugs; PCOS, polycystic ovarian syndrome

Using the definition of a 2-fold increase in seizure frequency during menses, it was concluded that nearly one third of women with intractable complex partial seizures may have catamenial epilepsy.⁸

Elevated estrogen or decreased progesterone levels can exacerbate seizure frequency. More specifically, progesterone or its metabolites (allopregnanolone) have been found to inhibit neuronal excitability through the modulation of GABA A receptors.^{9,10} Estrogen is believed to promote seizure activity by enhancing the NMDA receptor in the hippocampus.¹¹ The most vulnerable time for catamenial seizures in an ovulatory female is immediately prior to ovulation and prior to menses, when estrogen/progesterone ratios are high. In an anovulatory female, catamenial seizures typically occur during the latter half of the menstrual cycle due to unopposed elevated estrogen levels.

Treatment for catamenial seizures should begin with increasing the dosage of the prescribed AED

Address correspondence to: Sunila E. O'Connor MD, Department of Neurology, Section of Pediatric Neurology, 9000 W. Wisconsin Avenue, PO Box 1997, Milwaukee, WI 53201, email: soconnor@mcw.edu
© 2009 Pediatric Pharmacy Advocacy Group

in order to sustain a higher and more effective serum concentration. If side effects develop, the next approach would be to provide alternative medication. Acetazolamide, a mild diuretic, has been used "off-label" as an adjunctive agent since the 1950's. While the exact anti-epileptic effect is unknown, a 50% or greater reduction in catamenial seizure frequency has been retrospectively reported in 40% of patients taking acetazolamide.¹² Acetazolamide may be given immediately before and during menses at a dose of 4 mg/kg/day (not to exceed 1 g/day) in divided doses.⁹

Alternative therapies include perimenstrual clobazam (20-30 mg/day),¹³ combined oral contraception pills¹⁴ or progesterone.¹⁵ Cyclic progesterone supplementation in lozenge or suppository form (100-200 mg TID) has been shown to significantly improve catamenial epilepsy. This hormone was found to be most beneficial when given during the second half of the menstrual cycle. Progesterone should be tapered off over 3-4 days at the end of the cycle to prevent rebound catamenial seizures.^{16,17}

CONTRACEPTION

The efficacy of hormonal contraception may be diminished for women taking CYP-450 enzyme inducing AEDs, such as phenobarbital, phenytoin, carbamazepine and topiramate. These AEDs interact with combined estrogen/progesterone oral contraceptive pills. Increased hepatic metabolism can produce up to a 5-fold increase in contraception failure rates.^{18,19} The mechanism responsible for diminished contraceptive effectiveness involves an increase in estrogen and/or progestin metabolism which can reduce circulating hormone levels by as much as 50%.²⁰⁻²⁶ Progesterone-only birth control pills or levonorgestrel implants may be an ineffective method of birth control for women taking CYP-450 enzyme inducing AEDs for this reason.^{12,15} Medroxyprogesterone depot injections can also be affected by CYP-450 enzyme inducing AEDs. Therefore, these injections need to be given more frequently in women taking this class of AEDs.²⁷ Contraception alternatives for patients taking CYP-450 enzyme inducing AEDs include either high dose (50-100 mcg) estrogen agents, barrier contraception methods, or intrauterine devices to minimize the risk of unintended pregnancy.^{27,28}

There is now a new intrauterine copper T device that has been approved for nulliparous women.

Lamotrigine has been shown to decrease the efficacy of combined oral contraceptive pills by reducing the concentration of the progestin component. Furthermore, it has been suggested that progesterone-only pills can increase lamotrigine levels,²⁹ although a more recent study has not replicated these findings.³⁰ Conversely, a decrease of up to 70% in lamotrigine trough serum concentrations were noted in patients on combined hormonal contraception. However, during the placebo week or when a patient discontinues oral hormonal contraception, lamotrigine trough concentrations increase nearly 2-fold.³¹ As a result, lamotrigine concentrations should be closely monitored in women taking oral contraceptive pills. Alternatively, patients may encounter fewer variances in AED levels by utilizing continuous hormonal contraception without a placebo.

Non-enzyme inducing AEDs, such as valproate sodium, benzodiazepines, ethosuximide, zonisamide, levetiracetam, vigabatrin, gabapentin, pregabalin and tiagabine, do not interfere with the effectiveness of combined hormonal contraceptive pills.^{11,32}

Emergency contraception through the use of high dose progestins may be initiated following unprotected intercourse. While no study has examined the ideal dose for women taking AEDs, current recommendations are levonorgestrel 1.5 mg immediately following intercourse and 0.75 mg 12 hours later.³³

Reproductive Dysfunction

Women with epilepsy frequently experience reproductive abnormalities, specifically anovulatory cycles, menstrual irregularities and endocrine dysfunction. The etiologies are multifactorial but may result from altered hormonal functioning of the hypothalamus, pituitary, or ovaries as a result of the presence of seizures or AED exposure.³⁴ Fertility can be reduced by 20% to 40% when compared to women without seizures.^{35,36} A common cause of infertility is polycystic ovarian syndrome (PCOS). Signs and symptoms of the condition include obesity, hypercholesterolemia, hirsutism, acne, irregular periods, infertility and hypertension from circulating unbound androgens. Although polycystic ovaries are sometimes seen in these patients, their presence is not mandatory to make the diagnosis

of PCOS. The term PCOS is used when there is evidence of anovulatory cycles and elevated serum androgen levels. The syndrome is estimated to cause infertility in 4%-7% of women but is 2-3 times higher in women with epilepsy, particularly primary generalized epilepsy.³⁷⁻⁴⁰

Multiple asymptomatic ovarian cysts have been detected in 21%-23% of women.^{32,41,42} Studies have suggested that women with epilepsy are at higher risk for developing multiple ovarian cysts with detection rates ranging from 26%-41%.⁴³⁻⁴⁵ Primary generalized epilepsy, the use of valproate and obesity increase the risk of polycystic ovaries.^{39,46} Although not necessarily given the diagnosis of PCOS, up to 60% of women with epilepsy treated with valproate have multiple cysts in their ovaries. The prevalence in this cohort is highest in women receiving valproate prior to their mid-20s.^{47,48} Valproate, as part of a polytherapy regimen, appears to increase the risk of ovarian cysts more than monotherapy.⁴⁹ Simultaneous administration of oral contraceptive pills with valproate may be protective.⁵⁰ Women with polycystic appearing ovaries who are switched from valproate to another AED may demonstrate involution of ovarian cysts.^{39,41} Replacing valproate with lamotrigine resulted in normalization of endocrine function in 75% of women with polycystic ovaries, hyperandrogenism or both.⁴¹ The use of valproate within the preceding three years has been shown to produce nearly four times the increased risk of ovulatory failure when compared to women not taking the medication.⁵¹ Anovulatory cycles increase the risk of infertility among women in the reproductive age.

Pregnancy

Seizure frequency can increase in 17%-33% of women during pregnancy.^{52,53} Furthermore, seizure control may become difficult to manage in an additional 15%-35%.⁵⁴⁻⁵⁸ This finding occurs with all types of epilepsy and is not related to seizure control during previous pregnancies.⁴⁸ The risk of status epilepticus is 1%-2% during pregnancy.^{59,60} Seizure frequency is highest during labor and delivery, seen in approximately 5% of women.^{52,55} Another 1% will have seizures up to 24 hours after delivery.⁵¹

Many factors must be evaluated when treating pregnant women with epilepsy. Decisions include whether to continue AED treatment and, if so, which medications pose the least risk

to the mother and fetus. Optimizing AEDs becomes more challenging during pregnancy due to sleep deprivation, medication compliance and alterations in pharmacokinetics. Changes in serum AED concentration are the result of decreased binding to plasma proteins and enhanced drug elimination.^{61,62} Although the total AED concentration falls due to increased plasma volume and total body water, there is an increase in free (unbound) drug titers due to a reduction in albumin.^{63,64} This is especially seen with phenytoin, phenobarbital, valproate, carbamazepine and lamotrigine. As a result, unbound serum levels should be measured and compared to pregestational values. We recommend monitoring AED levels once every trimester, at delivery, and one to two weeks after delivery.

Counseling the patient regarding the treatment of epilepsy during pregnancy is essential due to the teratogenic potential of AEDs. Since a significant percentage of pregnancies are unplanned, it is important to discuss these issues with all women with epilepsy of childbearing age prior to conception. Antiepileptic medications have been shown to contribute to a higher rate of birth defects and learning disabilities.^{65,66} However, the discontinuation of AEDs may increase the risk of seizures, which can be harmful to both the mother and fetus. The maternal death rate is 10 times higher in women with epilepsy as compared to women without. The risk is believed to be secondary to an increased rate of seizures due to either subtherapeutic AED levels or a change in medication regimen.⁶¹ A general guideline is that a single, low-dose agent is preferred to polytherapy.⁶⁷ Holmes et al demonstrated an increased rate of "anticonvulsant embryopathy" in infants exposed to anticonvulsant drugs during gestation. The risk to the infant was directly correlated to the number of AEDs taken by the mother during pregnancy.⁶⁸

The risk of fetal malformation in the general population is 2%-4%. Prenatal exposure to AEDs is known to increase this risk to 4%-9%.^{63,69-73} Cardiac defects are seen in patients exposed to barbiturates, phenytoin or carbamazepine. The risk of a neural tube defect is associated with in utero exposure to carbamazepine (1%) and valproate (1%-2%).⁷⁴⁻⁷⁷ Genitourinary and/or skeletal anomalies have also been seen with valproate.⁷⁸ In at least one pregnancy registry, the risk of isolated cleft lip/palate is noted with fetal exposure to lamotrigine.⁷⁹

Multiple large scale studies demonstrate a dose-dependent and increased rate of fetal malformations following maternal valproate usage as compared to other AEDs.^{63,65,66,80,81} The North American Antiepileptic Drug Pregnancy Registry showed the risk of congenital malformations in fetuses exposed to valproate during the first trimester is higher than for all other forms of monotherapy.⁸² Similarly, the UK Epilepsy and Pregnancy Registry showed an increased birth defect incidence with valproate when compared to carbamazepine.⁶⁵ The International Lamotrigine Pregnancy Registry reported that major fetal malformations are four times more likely to occur when patients receive polytherapy including valproate versus those on lamotrigine monotherapy or polytherapy not including valproate.⁸³ Therefore, in order to attempt to minimize the risk of fetal defects, the lowest possible monotherapy dose should be sought *prior* to conception. Due to the use of supplemental folic acid, the incidence of neural tube defects in the United States has declined.⁸⁴ As a result, women with epilepsy are recommended to take 2-4 mg/day of folic acid. The dose should increase to 4 mg/day for those taking valproate due to elevated risk of fetal defects with this drug.⁸⁵

With respect to the newer antiepileptic medications, including lamotrigine, levetiracetam, topiramate, zonisamide and felbamate, the exact risks of fetal malformation during pregnancy remain unknown. There are a number of pregnancy registries that are currently ongoing and will provide credible percentage risks for fetal malformations in the next two years.

Breastfeeding

Most health organizations recommend breastfeeding due to the numerous benefits to the child, including reducing infections and decreasing the risk of immunological disorders.⁸⁶ The American Academy of Neurology also supports breastfeeding in women taking AEDs with close monitoring.⁸⁷ Although the amount of drug in breast milk is usually less than that delivered through the placenta, the infant's organs may not yet be equipped to metabolize AEDs. Phenobarbitol, ethosuximide and primidone are found in high concentration in breast milk and should be used with caution.⁸¹ Lamotrigine and zonisamide are also secreted in breast milk. One study demonstrated that infant lamotrigine concentrations at 2

weeks of age were 30% of the maternal drug concentrations.⁸⁸ Zonisamide concentration in breast milk is similar to maternal serum concentration.¹¹ The lactated concentration levels of phenytoin, carbamazepine and valproate are 3%-5% of the therapeutic dose and can be considered safer alternatives.^{81,82} Of the newer AEDs, levetiracetam secretion in breast milk is significantly lower than maternal plasma values.⁸⁹

While breastfeeding, AED concentrations may fluctuate due to increased metabolism and rates of clearance. As a result, AED concentrations need to be monitored while breastfeeding. In addition, as breastfeeding is weaned AED concentrations may increase and therefore, doses may need to be altered. Breastfed infants showing signs of lethargy, decreased feeding or weight loss should have serum AED concentrations measured.¹²

Bone Health

When compared to the general population, women with epilepsy are at increased risk of falls, fractures, osteoporosis and osteopenia.⁹⁰⁻⁹² Seizures are a known cause of fractures in patients with epilepsy due to an increased susceptibility to falls.⁹³ Mattson and Gidal reported a 2-6 fold increase in fractures in patients treated with AEDs.⁹⁴ Furthermore, AEDs have been shown to have a detrimental effect on bone quality.⁹⁵ Several studies found decreased serum calcium and/or vitamin D concentrations in patients treated with enzyme inducing AEDs.⁹⁶⁻⁹⁸ Other studies did not duplicate these findings.^{92,99} Bone mineral density is lower in women with epilepsy, especially those patients older than 40 years of age taking enzyme inducing AEDs longer than two years.¹⁰⁰ In addition, AEDs that do not induce CYP-450 enzymes are also linked to osteopenia.¹⁰¹ Women with epilepsy tend to reach menopause at an earlier age, thus contributing to bone loss.¹⁰² Animal studies have shown detrimental changes in bone quality after treatment with levetiracetam, phenytoin or valproate.¹⁰³

Mikati and colleagues demonstrated that high dose vitamin D supplementation (4000 international units for adults and 2000 international units for children) in patients on long term anti-epileptic medications increased bone mineral density.¹⁰⁴ These findings suggest that female patients on chronic AED therapy should strongly consider high dose vitamin D supplementation.

Other treatments include hormone replace-

Table. Clinical Pearls Regarding Antiepileptic Use in Women

- Catamenial epilepsy occurs in many women with epilepsy. Treatment for catamenial seizures should begin with a sustained increase in the patient's antiepileptic medication. Alternative adjunctive therapies include acetazolamide, oral contraceptives or progesterone.
- The efficacy of hormonal contraception diminishes in women who are taking CYP-450 enzyme inducing AEDs. Medroxyprogesterone depot injections can also be affected by CYP-450 enzyme inducing AEDs. Women taking CYP-450 enzyme inducing AEDs should use a higher dose of estrogen contraceptive drugs (50-100 µg), have more frequent depot injections or use barrier contraception methods. The new copper T intrauterine device has been approved in nulliparous women and may be an attractive alternative. None of these methods, except for barrier contraception methods, prevent sexually transmitted diseases.
- Women with epilepsy have a higher risk of reproductive dysfunction, including polycystic ovarian syndrome, multiple ovarian cysts, anovulatory cycles and infertility. These findings are more profound in women taking valproate.
- Women with epilepsy who are on AEDs and pregnant have an increased risk of fetal malformations. Prenatal exposure to AEDs is known to increase this risk to 4-9%. However, the vast majority of women with epilepsy deliver healthy babies. In addition, the cessation of AEDs during pregnancy increases the risk of seizures, including status epilepticus. In order to minimize the risk of fetal malformations, the lowest possible monotherapy AED dose should be sought prior to conception. In addition, all women of child-bearing age should have folate supplementation of 2-4 mg, 4 mg in women with epilepsy who are on valproate.
- Breastfeeding in women taking AEDs is safe, providing that there is close monitoring of the baby for potential side effects.
- Women with epilepsy are at higher risk for osteoporosis and fractures in comparison to their peers. Vitamin D and calcium supplementation are critical for maintenance of healthy bones. Bone mineral density should be routinely obtained in women with epilepsy.

ment therapy, bisphosphonates, estrogen receptor modulators and calcitonin. Large doses of vitamin D therapy in patients using AEDs did result in increased bone density.^{105,106} There continue to be many different treatment options; however, the most effective regimen has still not been determined. Due to the risks of potential bone loss in women receiving AEDs, bone density should be routinely monitored, especially in those with additional risk factors for poor bone health.

CONCLUSIONS

Treating women with epilepsy can be challenging. The clinician needs to be thoughtful about the choice of antiepileptic medications as it may effect reproductive planning and metabolic health. Careful and frequent assessments need to be made from menarche onward. A list of Clinical Pearls can be found in the Table.

DISCLOSURE The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.

REFERENCES

1. Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. *Neurology* 2006;66(6 Suppl 3):S37-45.
2. Newmark NE, Penry JK. Catamenial Epilepsy: a review. *Epilepsia* 1980;21:281-300.
3. Morrell MJ. Hormones and epilepsy through the lifetime. *Epilepsia* 1992;33 (suppl 4):S49-61.
4. Forcadass M, Pena MP, Salas PJ. Special situations in epilepsy: women and the elderly. *Neurologist* 2007;13(6 Suppl 1):S52-61.
5. Foldvary-Schaefer N, Harden C, Herzog A, Falcone T. Hormones and seizures. *Cleve Clin J Med* 2004;71(suppl 2):S11-18.
6. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? *Epilepsia* 1993;34:827-831.
7. Herzog AG, Harden CL, Liporace J, et al. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. *Ann Neurol* 2004;56:431-434.
8. Herzog AG, Klein P, Ransil B. Three patterns of catamenial epilepsy. *Epilepsia* 1997;38:1082-1088.

9. Gee KW, McCauley LD, Lan NC. A putative receptor for neurosteroids on the GABA receptor complex: the pharmacological properties and therapeutic potential of epalons. *Crit Rev Neurobiol* 1995;9:207-227.
10. Majewska MD, Harrison NL, Schwartz RD, et al. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. *Science* 1986;232:1004-1007.
11. Reddy DS. Role of neurosteroids in catamenial epilepsy. *Epilepsy Res* 2004;62:99-118.
12. Lim LL, Foldvary N, Mascha E, Lee J. Acetazolamide in women with catamenial epilepsy. *Epilepsia* 2001;42:746-749.
13. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. *J Neurol Neurosurg Psychiatry* 1984;47:1279-1282.
14. Crawford P. Best practice guidelines for the management of women with epilepsy. *Epilepsia* 2005;46(suppl 9):117-124.
15. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. *Neurology* 1999;52:1917-1918.
16. Herzog AG. Intermittent progesterone therapy and frequency of complex partial seizures in women with menstrual disorders. *Neurology* 1986;36:1607-1610.
17. Herzog AG. Progesterone therapy in complex partial and secondary generalized seizures. *Neurology* 1995;45:1660-1662.
18. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. *JAMA* 1986;256:238-240.
19. Coulam CB, Annegers JF. Do oral anticonvulsants reduce the efficacy of oral contraceptives? *Epilepsia* 1979;20:519-526.
20. Betts T, Crawford P. *Women and Epilepsy*. London, UK: Martin Dunitz, 1998;pp.27-28.
21. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. *CNS Drugs* 2002;16:263-272.
22. Back DJ, Bates M, Bowden A, et al. The interaction of phenobarbital and other anticonvulsants with oral contraceptive steroid therapy. *Contraception* 1980;22:495-503.
23. Crawford P, Chadwick, DJ, Martin C, et al. The interaction of phenytoin and carbamazepine with combined contraceptive steroids. *Br J Clin Pharmacol* 1990;30:892-896.
24. Saano V, Manfield CR, Reidenberg P, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. *Clin Pharmacol Ther* 1995;58:523-531.
25. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. *Epilepsia* 1997;38:317-323.
26. Doose DR, Wang SS, Padmanabhan M, et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and non-obese female subjects. *Epilepsia* 2003;44:540-549.
27. Zahn CA, Morell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. *American Academy of Neurology Practice Guidelines. Neurology* 1998;51:949-956.
28. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. *Neurology* 2006;67:S56-S58.
29. Schwenkhaugen AM, Stodieck SRG. Interaction between lamotrigine and progestin—only contraceptive pill containing desogestrel 75µg (Cerazette). *Epilepsia* 2004;45(suppl 7):144.
30. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. *Epilepsia* 2001;42:311-315.
31. Stodieck SRG, Schwenkhaugen AM. Lamotrigine plasma levels and combined monophasic oral contraceptives or a contraceptive vaginal ring, a prospective evaluation in 30 women. *Epilepsia* 2004;45(suppl 7):187.
32. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. *CNS Drugs* 2002;16:263-272.
33. Schwenkhaugen AM, Stodieck SRG. Which contraception in women with epilepsy? *Seizure* 2008;17:145-150.
34. Herzog AG. Menstrual disorders in women with epilepsy. *Neurology* 2006;66:S23-S28.
35. Dansky V, Andermann E, Andermann F. Marriage and fertility in epileptic patients. *Epilepsia* 1980; 21:261-271.

36. Wallace H, Shorvon S, Tallis R. Age specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. *Lancet* 1998;352:1970-1973.
37. Morrell MJ, Montouris G. Reproductive disturbances in patients with epilepsy. *Cleve Clin J Med* 2004;71(suppl 2):S19-S24.
38. Knochenhauser ES, Key TJ, Kashar-Miller M, et al. Prevalence of polycystic ovary syndrome in unselected black and white women of the southeastern united states: a prospective study. *J Clin Endocrinol Metab* 1998;83:3078-3082.
39. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. *Epilepsia* 2001;42:311-315.
40. Bilo L, Meo R, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. *Epilepsia* 1988;29:612-619.
41. Polson DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries - a common finding in normal women. *Lancet* 1988;1:870-872.
42. Clayton RN, Ogden V, Hodgkinson J, et al. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? *Clin Endocrinol* 1992;37:127-134.
43. Herzog AG, Seibel MM, Schomer DL, et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. *Arch Neurol* 1986;43:341-346.
44. Morrell MJ, Giudice L, Flynn K, et al. Predictors of ovulatory failure in women with epilepsy. *Ann Neurol* 2002;52:704-711.
45. Bilo L, Meo R, Valentino R, et al. Characterization of reproductive endocrine disorders in women with epilepsy. *J Clin Endocrinol Metab* 2001;86:2946-2949.
46. Isojärvi JIT, Rattya J, Myllyla VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. *Ann Neurol* 1998;43:446-451.
47. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. *N Engl J Med* 1993;329:1383-1388.
48. Isojarvi JIT, Laatikainen TJ, Knip M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. *Ann Neurol* 1996;39:579-584.
49. Murialdo G, Galimberti CA, Magri F, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. *J Endocrinol Invest* 1997;20:519-526.
50. Betts T, Yarrow H, Dutton N, Greenhill L, Rolfe T. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. *Seizure* 2003;12:323-329.
51. Morrell M, Giudice L, Flynn KL, et al. Predictors of ovarian failure in women with epilepsy. *Ann Neurol* 2002;52:704-711.
52. The EURAP study group, Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. *Neurology* 2006;66:354-360.
53. Yerby MS, Kaplan P, Tran T. Risks and management of pregnancy in women with epilepsy. *Cleve Clin J Med* 2004;71(Suppl 2):S25-S37.
54. Schmidt D, Beck-Managetta G, Janz D, Koch S. The effect of pregnancy on the course of epilepsy: a prospective study. In: Janz D, Dam M, Richens A, Eds. *Epilepsy, pregnancy and the child*. New York: Raven Press, 1982:39-49.
55. Hauser WA, Hesdorffer DC. Risk factors: In: Hauser WA, Hersdorffer DC, Eds, *Epilepsy: frequency, causes and consequences*. New York: Demos, 1990:53-100.
56. Bardy AH. Incidence of seizures during pregnancy, labor and puerperium in epileptic women: a prospective study. *Acta Neurol Scand* 1987;75:356-360.
57. Gjerde IO, Strandjord RE, Ulstein M. The course of epilepsy during pregnancy: a study of 78 cases. *Acta Neurol Scand* 1988;78:198-205.
58. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Epilepsy and pregnancy: a prospective study of seizure control in relation to free and total plasma concentrations of carbamazepine and phenytoin. *Epilepsia* 1994;35:122-130.

59. The EURAP Study Group. Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry. *Neurology* 2006;66:353-360.
60. Schmidt D. The effect of pregnancy on the natural history of epilepsy: a review of the literature. In: Janz D, Dam M, Bossi L, Helge H, Richens A, Schmidt D, Eds. *Epilepsy, Pregnancy, and the Child*. New York: Raven Press, 1982:3-14.
61. Perucca E. Drug metabolism in pregnancy, infancy and childhood. *Pharmacol Ther* 1987;34:129-143.
62. Pennell PB. Antiepileptic drug pharmacokinetics during pregnancy and lactation. *Neurology* 2003;61(suppl 2):S35-S42.
63. Anderson GD. Pregnancy-related changes in pharmacokinetics: a mechanistic-based approach. *Clin Pharmacokinet* 2005;44:989-1008.
64. Tomson T, Lindbom U, Ekqvist B, Sundqvist A. Disposition of carbamazepine and phenytoin in pregnancy. *Epilepsia* 1994;34:131-5.
65. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. *Epilepsia* 2004;45:1171-1175.
66. Adab N, Kini U, Vinten J, et al. The long term outcome of children born to mothers with epilepsy. *J Neurol Neurosurg Psychiatry* 2004;75:1575-1583.
67. Commission on genetics, pregnancy and the child, international league against epilepsy. Guidelines for the care of women of childbearing age with epilepsy. *Epilepsia* 1993;34:588-589.
68. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. *N Engl J Med* 2001;344:1132-1138.
69. Morrell M. Reproductive and Metabolic Disorders in women with epilepsy. *Epilepsia* 2003;44(suppl 4):11-20.
70. Morrow JJ, Russell A, Guthrie E, et al. Malformation risks of anti-epileptic drugs in pregnancy: a prospective study from the UK epilepsy and pregnancy register. *J Neurol Neurosurg Psychiatry* 2006;77:193-198.
71. Kaneko S, Battino D, Andermann R, et al. Congenital malformations due to anti-epileptic drugs. *Epilepsy Res* 1999;33:145-158.
72. Samren EB, van Duijn C, Koch S, et al. Maternal use of anti-epileptic drugs and the risk of major malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. *Epilepsia* 1997;38:981-990.
73. Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Ann Neurol* 1999;46:739-746.
74. Wide K, Winblad B, Kallen B. Major malformations in infants exposed to anti-epileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nationwide population-based register study. *Acta Paediatr* 2004;93:174-176.
75. Rosa FW. Spina Bifida in infants of women treated with carbamazepine during pregnancy. *N Engl J Med* 1991;324:674-677.
76. Omtzigt JGC, Los FJ, Grobee DE, et al. The risk of spina bifida aperta after first trimester exposure to valproate in a prenatal cohort. *Neurology* 1992;42(suppl 5):119-125.
77. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prenatally exposed to antiepileptic drugs. *Neurology* 1992;42(suppl 5):111-118.
78. Robert E, Lofkvist E, Mauguier F and Robert JM. Evaluation of drug therapy and teratogenic risk in Rhone-Alpes district population of pregnant women. *Eur Neurol* 1986;25:436-443.
79. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. *Neurology* 2008;70:2152-2158.
80. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian Register of Anti-epileptic Drugs in Pregnancy. *J Clin Neurosci* 2004;11:854-858.
81. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. *Neurology* 2005;64:1874-1878.
82. Wyszynski DF, Nambisan M, Surve T, et al. Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. *Neurology* 2005;64:961-965.

83. Cunnington M, Tennis P. International lamotrigine pregnancy registry scientific advisory committee. Lamotrigine and the risk of malformations in pregnancy. *Neurology* 2005;64:955-960.
84. Honein MN, Paulozzi LJ, Matthews TJ, et al. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. *JAMA* 2001;285:2981-2986.
85. Penovich P, Eck KE, Ecomomou VV. Recommendations for the care of women with epilepsy. *Cleve Cl J Med* 2004;71(suppl 2):S49-S57.
86. Ito S. Drug therapy for breast-feeding women. *N Engl J Med* 2000;343:118-126.
87. Morrell M. Guidelines for the care of women with epilepsy. *Neurology* 1998;51:S21-S27.
88. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. *Epilepsy Behav* 2004;5:102-105.
89. Greenhill L, Betts T, Yarrow H, et al. Breast milk levels of levetiracetam after delivery. *Epilepsia* 2004;45(suppl 7):230.
90. Souverein PC, Webb DJ, Petri H, et al. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research database. *Epilepsia* 2005;46:304-10.
91. Vestergaard P. Epilepsy, osteoporosis and fracture risk: a meta analysis. *Acta Neurol Scand* 2005;112:277-286.
92. Persson HBI, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. *Epilepsia* 2002;43:768-772.
93. Wirrell EC. Epilepsy-related injuries. *Epilepsia* 2006;47(Suppl 1):79-86.
94. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. *Epilepsy Behav* 2004;5(Suppl 2):S36-S40.
95. Pack A. Bone health in people with epilepsy: Is it impaired and what are the risk factors? *Seizure* 2008;17:181-186.
96. Weinstein RS, Bryce GF, Sappington LJ, et al. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. *J Clin Endocrinol Metab* 1984;58:1003-1009.
97. Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. *Ann Neurol* 2005;57:781-786.
98. Harden CL. Menopause and bone density issues for women with epilepsy. *Neurology* 2003;61:S16-S22.
99. Andress DL, Ozuna J, Tirschwell D, et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. *Arch Neurol* 2002;59:781-786.
100. Petty SJ, Paton LM, O'Brien TJ, et al. Effect of antiepileptic drug medication on bone mineral measures. *Neurology* 2005;65:1358-1365.
101. Cramer JA, Gordon J, Schachter S, Devinsky O. Women with epilepsy: hormonal issues from menarche through menopause. *Epilepsy Behav* 2007;11:160-178.
102. Harden CL, Koppel BS, Herzog AG, et al. Seizure frequency is associated with age of menopause in women with epilepsy. *Neurology* 2003;61:451-455.
103. Nissen-Meyer LS, Svalheim S, Tauboll E, et al. Levetiracetam, phenytoin, and valproate act differently on rat bone mass, structure, and metabolism. *Epilepsia* 2007;48:1850-1860.
104. Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. *Neurology* 2006;67:2005-2014.
105. Collins N, Maher J, Cole M, et al. A prospective study to evaluate the dose of vitamin D required to correct low 25-hydroxyvitamin D levels, calcium, and alkaline phosphatase in patients at risk of developing antiepileptic drug induced osteomalacia. *Q J Med* 1991;78:113-122.
106. Pedrera JD, Canal ML, Carvajal J, et al. Influence of vitamin D administration on bone ultrasound measurements in patients on anticonvulsant therapy. *Eur J Clin Invest* 2000;30:895-899.